Recent years, assessment of endothelial function by non-invasive brachial artery flow-mediated dilatation (FMD) has been widely used in cardiovascular research. Normal pregnancy is associated with increased nitric oxide (NO) production. Because L-homoarginine can act as a substrate for NO production, concentrations of L-homoarginine in normal pregnancy were assessed in the present study to test whether L-homoarginine is associated with endothelial function.

Methods and Results Healthy non-pregnant (n=61) and pregnant women (n=58) were studied in a cross-sectional study. L-homoarginine, L-arginine, asymmetric dimethylarginine and symmetric dimethylarginine concentrations were determined simultaneously by high-performance liquid chromatography. Endothelium-dependent brachial artery flow-mediated dilation (FMD) was measured by ultrasound. The serum L-homoarginine concentration was significantly higher during the second and the third trimesters compared with the levels in the non-pregnant women (4.8±1.7 and 5.3±1.5 vs 2.7±1.0 μmol/L, p<0.001, respectively). In line with this, FMD increased in response to pregnancy (p<0.05). Three months after delivery, the L-homoarginine concentrations and FMD were comparable to those recorded in the non-pregnant females. The concentration of L-homoarginine correlated significantly with gestational age (r=0.426, p=0.001) and brachial artery diameter and FMD (r=0.362, p=0.006 and r=0.306, p=0.022, respectively) in pregnancy.

Conclusions L-homoarginine appears to be increased during the second and third trimesters of pregnancy and may contribute to the enhanced endothelial function in normal pregnancies.

Key Words: Asymmetric dimethylarginine (ADMA); Flow-mediated vasodilatation; L-homoarginine; Nitric oxide; Pregnancy

In recent years, assessment of endothelial function by non-invasive brachial artery flow-mediated dilatation (FMD) technique has been widely used in cardiovascular research. FMD is enhanced throughout the pregnancy because of increased nitric oxide (NO) production.

Normal pregnancy is associated with profound hemodynamic changes that include enhanced vasodilatation. The enzyme, NO synthase (NOS, EC 1.14.13.39), and its competitive inhibitor, asymmetric dimethylarginine (ADMA), are suggested to represent a regulatory pathway, whereas symmetric dimethylarginine (SDMA), a stereoisomer of ADMA, does not directly inhibit NOS. In a normal pregnancy, ADMA levels are decreased in comparison with the levels found in non-pregnant females. Furthermore, it has been reported that plasma ADMA concentrations can become elevated in complicated pregnancies (eg, in preeclampsia).

L-homoarginine is a naturally occurring, basic, non-essential cationic amino acid that is believed to be derived from lysine. L-homoarginine has been detected in small amounts in all studied body fluids and organs (eg, serum, urine, cerebrospinal fluid, liver, kidney and brain), but its function is not yet clearly resolved. Several functional studies have demonstrated that L-homoarginine, in addition to L-arginine, can act as a substrate for NO production by NOS (Fig 1). Thus, L-homoarginine can be considered as an interesting compound for at least 3 reasons. First, L-homoarginine as such may play a role in the regulation of NO release and, like L-arginine, it is known to be a vasodilator. Second, earlier investigations have shown that cationic amino acids can modulate NO production in endothelial cells by altering cellular L-arginine uptake through transport mechanisms. Third, the level of L-homoarginine has been believed to be unchanged in a number of physiological and pathological conditions, so it has been used as an internal standard in studies evaluating the role of ADMA in a number of pathological conditions including preeclampsia.

In this study, we measured the serum concentrations of L-homoarginine and other molecules (eg, L-arginine, ADMA and SDMA) that may influence NO production. We
also investigated the hypothesis that serum L-homoarginine is associated with endothelial function in normal pregnancy.

**Methods**

**Study Populations**

The normal pregnant control group was derived from The Cardiovascular Risk in Young Finns Study, which is an ongoing 5-center follow-up study of atherosclerosis risk factors in Finnish children and adolescents. The individuals were randomly chosen from a national register, as previously described.27 There were 3,956 participants in 1980. In the follow-up study in 2001, there were 2,283 participants in the age range 24–39 years.28 In this study, we selected all (n=58) healthy pregnant women and non-pregnant control women (n=63) matched for age and smoking status. There were 6 smokers in both groups. Data collected about the menstrual cycle phases of the non-pregnant participants were divided into 4 categories: early follicular phase, late follicular phase, early luteal phase and late luteal phase. In the pregnant group, there were 13 women in the first trimester (≤14 weeks), 22 women in the second trimester (15–27 weeks) and 23 women in the third trimester (≥28 weeks). These women were examined with a cross-sectional study design to create reference values for the analytes.

The second group belonged to a prospective cohort study that was conducted at the Kuopio University Hospital, Finland. The patients were recruited from the Kuopio University Hospital maternity clinic where they were seen for clinical follow-up through January 2005 to December 2006. In this study, the study subjects with normal uncomplicated pregnancy were seen in the third trimester (n=15) and at 3 months postpartum.

The local ethics committee approved the 2 studies and all patients gave written informed consent before participating in the study.

**Blood Samples**

A blood sample was drawn from each subject for L-homoarginine, L-arginine, ADMA and SDMA assays. The sample was centrifuged at 2,000g for 10 min, and the serum was separated and stored frozen at −70°C until analysis.

**Measures**

Height and weight were measured, and body mass index (BMI) was calculated (weight/height²). Blood pressure was measured with a sphygmomanometer (Hawksley & Sons Ltd, Lancing, UK). Serum creatinine concentration was measured by photometric Jaffe assay (Olympus Diagnostica GmbH). Glomerular filtration rate was calculated by the Cockcroft-Gault formula.

**Vascular Ultrasound Measurements**

Brachial artery FMD was measured by ultrasound according to the guidelines. Ultrasound studies were performed using Sequoia 512 mainframes (Acuson, Mountain View, CA, USA) with 14.0 MHz linear array transducers. The segment of the brachial artery above the antecubital crease was imaged in the longitudinal plane at rest and during reactive hyperemia, induced by a sphygmomanometer cuff, which was placed around the forearm, inflated to a pressure of 250mmHg and deflated after 4.5 min. End-diastolic (incident with the R-wave) arterial diameter was measured at rest (baseline) and at 40, 60 and 80 s after cuff release from 5 s ultrasound image sets. The vessel diameter response in the scans taken after reactive hyperemia was expressed both as the absolute change in diameter (FMD) and as the percentage relative to the resting scan (FMD%). The 3-month between-visit coefficient of variation was 3.2% for brachial artery diameter measurements and 26.0% for FMD measurements.

**Assays**

Serum L-homoarginine, L-arginine, ADMA and SDMA levels were determined by high-performance liquid chromatography (HPLC) using precolumn derivatization with o-phthalaldehyde (OPA, Sigma, St Louis, MO, USA) according to the method described by Teerlink et al with minor modifications.29 In the HPLC method, the mean recoveries for ADMA, SDMA, L-homoarginine and L-arginine from spiked sample were 95, 95, 100 and 113%, respectively. The intra-assay CVs of the plasma pool for ADMA (0.643μmol/L), SDMA (0.654μmol/L), L-homoarginine (1.2μmol/L) and L-arginine (58.6μmol/L) were 2.5, 5.6, 1.4 and 2.5% (n=9), respectively. Interassay CVs of 10 series of samples for ADMA, SDMA, L-homoarginine and L-arginine were 4.2, 3.7, 2.9 and 2.8%, respectively. N6-monomethyl-L-arginine (Fluka, Buchs, Switzerland) was used as an internal standard.
towards term.

higher than during the first trimester. Maternal L-arginine concentrations of L-homoarginine were (4.8±1.7 and 5.3±1.5 vs 2.7±1.0 compared with the levels in non-pregnant control women in the first trimester, but significantly increased concentrations of L-arginine during normal pregnancy (Table 1).

Serum L-homoarginine concentrations remained unchanged arginine concentrations during normal pregnancy (Table 1).

Kruskal-Wallis test and the non-parametric Mann-Whitney test. In linear regression analysis, the concentration of serum analytes were calculated by Spearman correlation coefficient analysis to evaluate the independent correlates of FMD%. A distribution. In addition, multiple-regression analysis was L-homoarginine was log-transformed because of the skewed

Statistical Analysis

Data are presented as mean±standard deviation (SD). Comparisons between groups were performed with the Kruskal-Wallis test and the non-parametric Mann-Whitney U-test. Bonferroni correction was used with the Mann-Whitney U-test for analyte comparisons between different trimesters of pregnancy and the control group. The correlations between L-homoarginine concentration and other analytes were calculated by Spearman correlation coefficient test. In linear regression analysis, the concentration of serum L-homoarginine was log-transformed because of the skewed distribution. In addition, multiple-regression analysis was used to evaluate the independent correlates of FMD%. A computer software program (SPSS 11.5 for Windows; SPSS Inc, Chicago, IL, USA) was used. A probability level <0.05 was considered statistically significant.

Results

We recorded significant changes in maternal L-homoarginine concentrations during normal pregnancy (Table 1). Serum L-homoarginine concentrations remained unchanged in the first trimester, but significantly increased concentrations were observed in the second and third trimesters as compared with the levels in non-pregnant control women (4.8±1.7 and 5.3±1.5 vs 2.7±1.0 mol/L, p<0.001 for both, respectively). Likewise, in the second (p<0.05) and third trimesters (p<0.01) concentrations of L-homoarginine were higher than during the first trimester. Maternal L-arginine concentrations decreased significantly in the first trimester (p<0.05) and then increased near to the control levels towards term.

L-homoarginine concentrations detected varied between 1.4 and 9.4 mol/L during pregnancy and between 1.2 and 6.2 mol/L in the non-pregnant control group. According to the correlation analysis, which included all pregnant women, the L-homoarginine concentration correlated significantly with gestational age (r=0.426, p=0.001) (Fig 2A). In addition, both baseline brachial artery diameter and FMD (Fig 2B) were positively correlated with serum L-homoarginine concentration (r=0.362, p<0.001 and r=0.306, p=0.022, respectively) in pregnant women, but not in non-pregnant females. In the multivariable regression analysis adjusted for brachial artery baseline diameter, FMD% was significantly associated with L-homoarginine concentration (standardized coefficient β=0.192, p=0.015). When L-homoarginine, gestational age, total cholesterol and brachial artery baseline diameter were added to the model, only brachial artery baseline diameter (p<0.007) remained significantly associated with FMD%. After delivery, the concentration of L-homoarginine, the brachial artery diameter and FMD (2.2±0.8 μmol/L, 3.1±0.32 mm and 0.22±0.09 mm, respectively) were comparable to the values in non-pregnant females. L-homoarginine concentrations were not associated with L-arginine or dimethylarginines during pregnancy or in non-pregnant women. In non-pregnant women, FMD parameters, lipids, L-homoarginine, L-arginine and dimethylarginines did not vary significantly during the different phases of the menstrual cycle.

The data summarizing the dimethylarginine concentrations in all trimesters of normal pregnancy are shown in Table 1. The concentrations of ADMA were similar in all trimesters, whereas slight, probably clinically unimportant, biphasic changes were observed in maternal SDMA concent-

<p>| Table 1 Clinical Characteristics and Serum L-Homoarginine, L-Arg and Dimethylarginine Levels in Non-Pregnant Controls and in the Trimesters of Normal Pregnancy |</p>
<table>
<thead>
<tr>
<th>Non-pregnant controls</th>
<th>Trimester I (n=13)</th>
<th>Trimester II (n=22)</th>
<th>Trimester III (n=23)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>31±5</td>
<td>29±4</td>
<td>32±4</td>
<td>31±5</td>
</tr>
<tr>
<td>Height (m)</td>
<td>1.68±0.06</td>
<td>1.65±0.05</td>
<td>1.66±0.06</td>
<td>1.65±0.07</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>66.9±11.6</td>
<td>65.9±9.1</td>
<td>70.2±10.3</td>
<td>75.2±14.0</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>23.9±4.5</td>
<td>24.3±4.3</td>
<td>25.2±3.4</td>
<td>27.7±4.4</td>
</tr>
<tr>
<td>Gestation week</td>
<td>11±3</td>
<td>11±3</td>
<td>20±4</td>
<td>31±3</td>
</tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>116±14</td>
<td>111±10</td>
<td>110±12</td>
<td>113±13</td>
</tr>
<tr>
<td>Diastolic BP (mmHg)</td>
<td>72±10</td>
<td>66±5</td>
<td>64±7</td>
<td>70±9</td>
</tr>
<tr>
<td>Cholesterol (mmol/L)</td>
<td>5.0±0.90</td>
<td>4.56±0.71</td>
<td>5.92±1.03</td>
<td>7.07±0.94</td>
</tr>
<tr>
<td>HDL-C (mmol/L)</td>
<td>1.44±0.30</td>
<td>1.45±0.30</td>
<td>1.70±0.24</td>
<td>1.81±0.42</td>
</tr>
<tr>
<td>LDL-C (mmol/L)</td>
<td>3.10±0.84</td>
<td>2.61±0.45</td>
<td>3.44±0.67</td>
<td>4.15±0.83</td>
</tr>
<tr>
<td>Triglycerides (mmol/L)</td>
<td>1.15±0.44</td>
<td>1.11±0.52</td>
<td>1.73±0.66</td>
<td>2.46±0.79</td>
</tr>
<tr>
<td>Creatinine (μmol/L)</td>
<td>66±8</td>
<td>59±9</td>
<td>50±5##</td>
<td>53±2*†</td>
</tr>
<tr>
<td>GFR (ml/min)</td>
<td>137±3.4</td>
<td>156±35</td>
<td>190±39##*</td>
<td>189±48*†</td>
</tr>
<tr>
<td>Brachial artery diameter (mm)</td>
<td>3.07±0.32</td>
<td>3.02±0.24</td>
<td>3.35±0.31</td>
<td>3.25±0.26</td>
</tr>
<tr>
<td>FMD (mm)</td>
<td>0.28±0.12</td>
<td>0.24±0.09</td>
<td>0.32±0.14</td>
<td>0.36±0.17</td>
</tr>
<tr>
<td>FMD (%)</td>
<td>9.43±4.07</td>
<td>7.98±3.01</td>
<td>10.17±4.96</td>
<td>11.12±5.31</td>
</tr>
<tr>
<td>L-homoarginine (μmol/L)</td>
<td>2.7±1.1</td>
<td>3.1±1.4</td>
<td>4.8±1.7##†</td>
<td>5.3±1.5##</td>
</tr>
<tr>
<td>L-Arg (μmol/L)</td>
<td>106±17.1</td>
<td>87.1±11.5##</td>
<td>97.2±17.2</td>
<td>94.7±16.1</td>
</tr>
<tr>
<td>ADMA (μmol/L)</td>
<td>0.57±0.07†††</td>
<td>0.513±0.082</td>
<td>0.518±0.376#**</td>
<td>0.516±0.964##</td>
</tr>
<tr>
<td>SDMA (μmol/L)</td>
<td>0.430±0.058</td>
<td>0.394±0.061</td>
<td>0.351±0.033*</td>
<td>0.397±0.056##</td>
</tr>
<tr>
<td>L-Arg/ADMA ratio</td>
<td>176.1±33.3</td>
<td>174.7±43.7</td>
<td>190.2±38.2</td>
<td>184.6±39.1</td>
</tr>
<tr>
<td>ADMA/SDMA ratio</td>
<td>1.36±0.19</td>
<td>1.31±0.15</td>
<td>1.48±0.20##††</td>
<td>1.31±0.15##</td>
</tr>
</tbody>
</table>

Values are mean±SD. Data were compared by Mann-Whitney U test with a Bonferroni correction; p value is calculated by Kruskall-Wallis test between all groups.

*p<0.001 vs control; **p<0.01 vs control; †p<0.05 vs control; ††p<0.05 vs trimester I; †‡p<0.01 vs trimester I.

2p<0.05 vs trimester II; †‡p<0.01 vs trimester II.

L-Arg, L-arginine; BMI, body mass index; BP, blood pressure; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; GFR, glomerular filtration rate; FMD, flow-mediated dilatation; ADMA, asymmetric dimethylarginine; SDMA, symmetric dimethylarginine.
trations, with the second trimester level being statistically significantly lower than those for the third trimester or in the non-pregnant state. The L-arginine/ADMA ratio, an indicator of NO production by NOS, remained unchanged in all trimesters. The ADMA/SDMA ratio, an index of the ADMA degrading enzyme, dimethylarginine dimethylamino-hydrolase activity displayed a statistically significant increase in the second trimester compared with the ratio in the first and third trimesters (p<0.05).

**Discussion**

The present study demonstrated increased maternal L-homoarginine concentrations in the second and third trimesters of pregnancy. In addition, we observed that the L-homoarginine concentration was associated with FMD, a non-invasively measured marker of endothelial function. These findings suggest that L-homoarginine has a biological function in normal pregnancy, which may be related to endothelial-dependent vasodilatation.

The difference between the pregnant and non-pregnant group in the L-homoarginine concentrations cannot be attributed to intra-individual variability, which was found to be in the order of 14% in the study of Blackwell et al where the mean L-homoarginine concentration in the normal population was 1.99 μmol/L (n=100). They did not find any significant differences in L-homoarginine concentrations between female and male subjects. The mechanism behind our observed elevation of L-homoarginine concentration during pregnancy remains unclear, but the present results imply that an L-homoarginine concentration exceeding 6 μmol/L may be high in a young non-pregnant woman whereas in a pregnant woman such a concentration could be common.

One explanation for the elevated L-homoarginine in pregnancy could be the increased expression of the L-arginine:glycine amidinotransferase gene after its induction by estrogen. Normally, the maternal estrogen concentration increases substantially during pregnancy, and estrogen has been shown to modulate the expression of the L-arginine: glycine amidinotransferase gene. Using an animal model, Ryan et al have shown that this enzyme can convert lysine to L-homoarginine in reactions analogous to those of the urea cycle (Fig 1) in which lysine replaces ornithine in the rat kidney. Guanidinated amino acids, such as L-homoarginine, are also known to be more stable than lysine when incorporated into proteins. One possibility with regard to guanidinated proteins is that the L-homoarginine is being transformed back to lysine by arginase in the liver and kidneys thus preventing lysine deficiency.

It has been demonstrated that natural hormonal fluctuation during the menstrual cycle may reflect endothelial function, and FMD% has been shown to decrease in the early luteal phase compared with the follicular phase and increase again in the late luteal phase. In the present study we did not measure estrogen or other hormonal levels, so we could not examine the correlation between estrogen and L-homoarginine concentrations or endothelial function parameters. However, there were data for the menstrual cycle phase of non-pregnant participants and these groups were rather evenly divided, although the number of participants in each group was small (n=10–13). A non-significant decreasing trend in FMD% was found in the early luteal phase group, but lipids, L-homoarginine, L-arginine and dimethylarginines did not vary significantly during the 4 phases of the menstrual cycle.

Normal pregnancy is associated with profound hemodynamic changes, including NO-mediated endothelium-dependent vasodilatation. Several functional studies have demonstrated that L-homoarginine, in addition to L-arginine, can act as a substrate for NO production by NOS (Fig 1) and pregnancy is associated with reprogramming of cell signalling in response to the increased consumption of NO. Gerritsen et al have observed L-homocitrulline in the urine of newborns, but not in adults, and NOS enzyme is...
known to convert L-homoarginine to L-homocitrulline releasing NO. However, kinetic analysis has revealed that L-arginine exhibits a 2-fold faster maximal binding rate to the NOS enzyme than L-homoarginine, and there is a huge excess of L-arginine in circulation, so the functional role of L-homoarginine might be of only minor importance in NO-dependent endothelium-derived vasodilatation. On the other hand, very low ADMA levels are believed to inhibit NOS activity by competing with the substrate L-arginine when the concentration of L-arginine is several 100-fold higher than the concentration of ADMA. In addition, earlier investigations have shown that cationic amino acids can modulate NO production in endothelial cells by altering cellular L-arginine transport through transport mechanisms.

We could not find any association between the maternal L-homoarginine concentration and the ADMA or SDMA concentration, and it is likely that the physiological concentration of L-homoarginine is not a key regulator of ADMA and SDMA. Because L-homoarginine is widely used as an internal standard in medical studies when measuring the serum or plasma level of L-arginine, ADMA or SDMA by HPLC, this increase in the L-homoarginine concentration during pregnancy should be kept in mind to avoid erroneous results.

In a recent study, it was observed that the whole-body NO synthesis rate was reduced and FMD% was 36% lower in healthy volunteers with hypercholesterolemia compared with controls, although there were no differences in the plasma ADMA concentrations between the hyper- and normocholesterolemic participants. We have previously shown in the Young Finns cohort study that ADMA is inversely related to brachial FMD, we have also compared the changes in the lipid concentrations and the concentrations of L-arginine, ADMA and SDMA and FMD in normal pregnant women and healthy non-pregnant controls. In the present study, ADMA, SDMA and L-arginine concentrations were decreased in normal pregnancy, despite marked hypercholesterolemia, and they were not correlated with FMD. Regardless of hypercholesterolemia, the FMD values were concomitantly enhanced towards the end of pregnancy.

**Study Limitations**

There is a large long-term variation found in FMD measurements, although the long-term reproducibility of brachial artery diameter measurements is excellent in our HPLC assay, the intra-assay and interassay variations of L-arginine, dimethylarginines and L-homoarginine were low. Our study population belongs to a retrospective non-longitudinal study and has the flaws of a small cross-sectional study. In addition, several physiologic, metabolic and immunologic changes, which interact with each other, take place in the maternal body during normal pregnancy. Thus, when statistical significance is measured by multivariable models, it may, however, reflect overcorrection, because there are strong correlations between the included parameters. In addition, when evaluating the results, it is important to notice that correlation analysis in cross-sectional studies demonstrates associations between analyses that do not necessarily imply causality.

In summary, the present results reveal that the L-homoarginine concentration increases significantly in the second and third trimesters of normal pregnancy and may contribute to enhanced endothelial function.

**Acknowledgments**

The authors would like to thank Mrs. Raaja Isonäki for skilful technical assistance and Docent Reijo Laaksonen for valuable comments to the manuscript. This study was supported by grants from Kuopio University Hospital (grant no. 15863 and EVO grant no. 5190 and 5031320), EVO-grants from Turku and Academy of Finland (grant no. 77841 and 210283), Social Insurance Institution and The Finnish Foundation for Cardiovascular Research.

**References**


Circulation Journal Vol.72, November 2008


